Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ophtha.2023.12.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health-seeking behaviors during an outbreak of acute conjunctivitis in Central India.
Indian J Ophthalmol
January 2025
Department of Cornea and Anterior Segment, MGM Eye Institute, Raipur, Chhattisgarh, India.
Purpose: To report the health-seeking behaviors of individuals with acute viral conjunctivitis during an outbreak.
Methods: A cross-sectional survey was carried out in the Raipur district of Chhattisgarh after an outbreak of acute conjunctivitis in July-August 2023.
Results: The treatment choices were pharmacies (51.
Allergen immunotherapy.
Allergy Asthma Clin Immunol
December 2024
Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Allergen immunotherapy (AIT) is a potentially disease-modifying therapy that is effective for the treatment of allergic rhinitis/conjunctivitis, allergic asthma and stinging insect hypersensitivity. The decision to proceed with AIT should be made on a case-by-case basis, based on a comprehensive evaluation of the patient, allergy testing and a thorough discussion with the patient about treatment goals, risks vs. benefits, and long-term commitment to the treatment plan.
View Article and Find Full Text PDFImpact of particulate matter and air pollution on ocular surface disease: A systematic review of preclinical and clinical evidence.
Ocul Surf
December 2024
Ophthalmology, Loyola University Chicago, Maywood, IL, USA; Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, IL, USA. Electronic address:
Purpose: Exposure to particulate matter (PM) and air pollution has been implicated in the etiology of ocular surface diseases (OSD). The purpose of this systematic review is to evaluate and synthesize peer-reviewed literature on the impact of PM exposure on the ocular surface, integrating results from preclinical in vitro and in vivo studies with clinical findings to provide a comprehensive understanding of molecular mechanisms, physiological effects, clinical implications, and potential therapies to target acute and chronic PM-induced ocular toxicity.
Methods: A systematic literature search was performed using PubMed and EMBASE over the period from 2009 to 2024 following the recommendations for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.
Conjunctival Phlyctenule and Nodular Scleritis in a Patient with Previous Herpes Simplex Virus-2 Exposure: Causative Agent or Innocent Bystander?
Case Rep Ophthalmol
November 2024
Department of Ophthalmology, University of Florida, Gainesville, FL, USA.
Article Synopsis
- Phlyctenular keratoconjunctivitis is an inflammatory eye condition caused by a type IV hypersensitivity reaction, characterized by inflamed nodules, and can progress to more severe issues like nodular scleritis, particularly in patients with underlying infections like HSV-2.
- A 66-year-old woman initially diagnosed with keratoconjunctivitis displayed symptoms that progressed to conjunctival phlyctenule, where HSV-2 was identified as a contributing factor, and her condition improved significantly with oral antiviral treatment.
- This case emphasizes the need for proper diagnosis and treatment options for ocular inflammatory diseases, advocating for thorough testing and close follow-up to ensure effective management and personalized care for patients.
Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Expert Opin Drug Saf
November 2024
Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Article Synopsis
- * Researchers analyzed data from January 2022 to June 2024, identifying 1,820 adverse event reports and noting that some untapped issues like eye pruritus and pneumonia pneumococcal were highlighted alongside known reactions like injection site irritation.
- * The findings provide a deeper understanding of tralokinumab's safety profile, which can help clinicians mitigate risks and manage potential side effects in patients receiving this treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!